Ageing gender-specific "Biomarkers of Homeostasis", to protect ourselves against the diseases of the old age

Immunity and Ageing

Volumn 11, Issue 1, 2014, Pages

  Berghella, Anna M ^a   Contasta, Ida ^a   Marulli, Giuseppe ^b   D'Innocenzo, Carlo ^b   Garofalo, Ferdinando ^b   Gizzi, Francesca ^b   Bartolomucci, Marco ^b   Laglia, Giacomo ^b   Valeri, Marisa ^b   Gizzi, Mario ^b   Friscioni, Mauro ^b   Barone, Mario ^b   Del Beato, Tiziana ^a   Secinaro, Enzo ^c   Pellegrini, Patrizia ^a  

^a INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^b Poliambulatorio Casa della Salute Nucleo San Gregorio   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Age related pathologies; Clinical homeostatic biomarkers; Gender immune pathways; Immunosenescence; Inflammation; Pathology risk indices; Personalized therapies; Prevention programs

Indexed keywords

BIOLOGICAL MARKER; CD30 ANTIGEN; CYTOKINE; THIOREDOXIN 1;

AGING; ARTICLE; CHRONIC INFLAMMATION; COMPETENCE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; HEALTH CARE QUALITY; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INTERVENTION STUDY; LONGEVITY; MALE; NEUROPATHOLOGY; PATIENT IDENTIFICATION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SENESCENCE; SEX DIFFERENCE;

EID: 84893937173     PISSN: None     EISSN: 17424933     Source Type: Journal    
DOI: 10.1186/1742-4933-11-3     Document Type: Article

References (87)

1. Kevin Howcroft T, Campisi J, Louis GB, Smith MT, Wise B, Wyss-Coray T, Augustine AD, McElhaney JE, Kohanski R, Sierra F. The role of inflammation in age-related disease. Aging 2013, 1:84-93.
2. Licastro F, Caruso C. Predictive diagnostics and personalized medicine for the prevention of chronic degenerative diseases. Immun Ageing 2010, 16:7.
3. Blagosklonny MV. Answering the ultimate question "what is the proximal cause of aging?". Aging 2012, 4:861-877. 3615154, 23425777.
4. Pietrantonio F, DE Braud F, DA Prat V, Perrone F, Pierotti MA, Gariboldi M, Fanetti G, Biondani P, Pellegrinelli A, Bossi I, DI Bartolomeo M. A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res 2013, 33:1257-1266.
5. Kavathia N, Alka J, Walston J, Beamer BA, Fedarko NS. Serum markers of apoptosis decrease with age and cancer stage. Aging 2009, 1:652-663. 2806040, 20157546.
6. Osoriov FG, López-Otín C, Freije JMP. NF-κB in premature aging. Aging 2012, 4:726-727. 3560436, 23211391.
7. Vasto S, Candore G, Balistreri CR, Caruso M, Colonna-Romano G, Grimaldi MP, Listi F, Nuzzo D, Lio D, Caruso C. Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev 2007, 128:83-91. 10.1016/j.mad.2006.11.015, 17118425.
8. Vasto S, Candore GD, Nuzzo D, Mocchegiani E, Di Bona D, Caruso C. Inflammation, genes and zinc in Alzheimer's disease. Brain Res Rev 2008, 58:96-105. 10.1016/j.brainresrev.2007.12.001, 18190968.
9. Candore G, Colonna-Romano G, Balistreri CR, Di Carlo D, Grimaldi MP, Listi F, Nuzzo D, Vasto S, Lio D, Caruso C. Biology of longevity: role of the innate immune system. Rejuvenation Res 2006, 9:1.
10. De Guire V, Robitaille R, Tétreault N, Guérin R, Ménard C, Bambace N, Sapieha P. Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: promises and challenges. Clin Biochem 2013,
11. Capri M, Salvioli S, Monti D, Caruso C, Candore G, Vasto S, Olivieri F, Marchegiani F, Sansoni P, Baggio G, Mari D, Passarino G, De Benedictis G, Franceschi C. Human longevity within an evolutionary perspective: the peculiar paradigm of a post-reproductive genetics. Exp Gerontol 2008, 43:53-60. 10.1016/j.exger.2007.06.004, 17692487.
12. Barker PE, Murthy M. Biomarker validation for aging: lessons from mtDNA heteroplasmy analyses in early cancer detection. Biomark Insight. 2009, 4:165-179.
13. Mantovani A. Cancer: inflaming metastasis. Nature 2009, 457:36-37.
14. Anisimov VN, Bartke A, Barzilai N, Batin MA, Blagosklonny MV, Brown-Borg H, Budovskaya Y, Campisi J, Friguet B, Fraifeld V, Franceschi C, Gems D, Gladyshev V, Gorbunova V, Gudkov AV, Kennedy B, Konovalenko M, Kraemer B, Moskalev A, Petropoulos I, Pasyukova E, Rattan S, Rogina B, Seluanov A, Shaposhnikov M, Shmookler Reis R, Tavernarakis N, Vijg J, Yashin A, Zimniak P. The second international conference "genetics of aging and longevity". Aging 2012, 4:305-317.
15. Bruunsgaard H. The clinical impact of systemic low-level inflammation in elderly populations. With special reference to cardiovascular disease, dementia and mortality. Dan Med Bull 2006, 53:285-309.
16. Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol 2004, 39:687-699. 10.1016/j.exger.2004.01.009, 15130663.
17. Velarde MC, Demaria M, Campisi J. Senescent cells and their secretory phenotype as targets for cancer therapy. Interdiscip Top Gerontol 2013, 38:17-27. doi:10.1159/000343572.
18. Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol 2013, 75:685-705. doi:10.1146/annurev-physiol-030212-183653, 10.1146/annurev-physiol-030212-183653, 23140366.
19. Sansoni P, Vescovini R, Fagnoni F, Biasini C, Zanni F, Zanlari L, Telera A, Lucchini G, Passeri G, Monti D, Franceschi C, Passeri M. The immune system in extreme longevity. Exp Gerontol 2008, 43:61-65. 10.1016/j.exger.2007.06.008, 17870272.
20. De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett 2005, 579:2035-2039. 10.1016/j.febslet.2005.02.055, 15811314.
21. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia aging study. Ann Neurol 2002, 52:168-174. 10.1002/ana.10265, 12210786.
22. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006, 15:381-384. 10.1158/1055-9965.EPI-05-0626, 16492932.
23. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007, 65:S253-S259. 10.1301/nr.2007.dec.S253-S259, 18240558.
24. Zhu J, Quyyumi AA, Norman JE, Csako G, Waclawiw MA, Shearer GM, Epstein SE. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol 2000, 85:140-146. 10.1016/S0002-9149(99)00653-0, 10955367.
25. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation and cancer. Cell 2010, 140:883-899. 10.1016/j.cell.2010.01.025, 2866629, 20303878.
26. Sprott RL. Biomarkers of aging and disease: introduction and definitions. Exp Gerontol 2010, 45:2-4. 10.1016/j.exger.2009.07.008, 19651201.
27. Terry DF, Wilcox MA, McCormick MA, Pennington JY, Schoenhofen EA, Andersen SL, Perls TT. Lower all-cause, cardiovascular, and cancer mortality in centenarians' offspring. J Am Geriatr Soc 2004, 52:2074-2076. 10.1111/j.1532-5415.2004.52561.x, 15571545.
28. Miyaishi O, Ando F, Matsuzawa K, Kanawa R, Isobe K. Cancer incidence in old age. Mech Ageing Dev 2000, 117:47-55. 10.1016/S0047-6374(00)00136-6, 10958922.
29. Franceschi C, Motta L, Motta M, Malaguarnera M, Capri M, Vasto S, Candore G, Caruso C. The extreme longevity: the state of the art in Italy. Exp Gerontol 2008, 43:45-52. 10.1016/j.exger.2007.06.006, 17703905.
30. De Pinho RA. The age of cancer. Nature 2000, 408:248-254. 10.1038/35041694, 11089982.
31. Vasto S, Carruba G, Lio D, Colonna-Romano G, Di Bona D, Candore G, Caruso C. Inflammation, ageing and cancer. Mech Ageing Dev 2009, 130:40-45. 10.1016/j.mad.2008.06.003, 18671998.
32. Viganò S, Perreau M, Pantaleo G, Harari A. Positive and negative regulation of cellular immune responses in physiologic conditions and diseases. Clin Dev Immunol 2012, 485781. doi:10.1155/2012/485781.
33. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 2003, 8:223-246.
34. Candore G, Balistreri CR, Listi{dotless} F, Grimaldi MP, Vasto S, Colonna-Romano G, Franceschi C, Lio D, Caselli G, Caruso C. Immunogenetics, gender, and longevity. Ann N Y Acad Sc 2006, 1089:516-537.
35. Franceschi C, Motta L, Motta M, Malaguarnera M, Capri M, Vasto S, Candore G, Caruso C. The extreme longevity: the state of the art in Italy. Exp Gerontol 2008, 43:45-52. 10.1016/j.exger.2007.06.006, 17703905.
36. Liu LY, Schaub MA, Sirota M, Butte AJ. Sex differences in disease risk from reported genome-wide association study findings. Hum Genet 2012, 131:353-364. 10.1007/s00439-011-1081-y, 3260375, 21858542.
37. Grossman CJ. Possible underlying mechanisms of sexual dimorphism in the immune response, fact and hypothesis. Journal of Steroid Biochemistry 1989, 34:241-251. 10.1016/0022-4731(89)90088-5, 2696846.
38. Schuurs AH, Verhuel HA. Effects of gender and sex steroids on the immune response. Journal of Steroid Biochemistry 1990, 35:157-172. 10.1016/0022-4731(90)90270-3, 2407902.
39. Cannon JC, St-Pierre BA. Gender differences in host defense mechanisms. J Psychiatr Res 1997, 31:99-113. 10.1016/S0022-3956(96)00055-6, 9201652.
40. Lee JH, Ulrich B, Cho J, Park J, Kim CH. Progesterone promotes differentiation of human cord blood fetal T cells into T regulatory cells but suppresses their differentiation into Th17 cells. J Immunol 2011, 187:1778-1787. 10.4049/jimmunol.1003919, 3155957, 21768398.
41. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol 2001, 2:777-780. 10.1038/ni0901-777, 11526384.
42. McCarthy M. The " gender gap" in autoimmune disease. Lancet 2000, 356:1088. 10.1016/S0140-6736(05)74535-9, 11009154.
43. Rohleder N, Schommer NC, Hellhammer DH, Engel R, Kirschbaum C. Sex differences in glucocorticoid sensitivity of proinflammatory cytokine production after psychosocial stress. Psychosom Med 2001, 63:966-972.
44. Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G, Bonafè M, Cavallone L, Franceschi C, Caruso C. Gender-specific association between -1082 IL-10 promoter polymorphism and longevity. Genes Immun 2002, 3:30-33. 10.1038/sj.gene.6363827, 11857058.
45. Franceschi C, Motta L, Valensin S, Rapisarda R, Franzone A, Berardelli M, Motta M, Monti D, Bonafè M, Ferrucci L, Deiana L, Pes GM, Carru C, Desole MS, Barbi C, Sartoni G, Gemelli C, Lescai F, Olivieri F, Marchegiani F, Cardelli M, Cavallone L, Gueresi P, Cossarizza A, Troiano L, Pini G, Sansoni P, Passeri G, Lisa R, Spazzafumo L, et al. Do men and women follow different trajectories to reach extreme longevity? Italian multicenter study on centenarians. Aging 2000, 12:77-84.
46. Balistreri CR, Candore G, Accardi G, Bova M, Buffa S, Bulati M, Forte GI, Listi F, Martorana A, Palmeri M, Pellicano M, Vaccarino L, Scola L, Lio D, Colonna-Romano G. Genetics of longevity. Data from the studies on Sicilian centenarians. Immun Ageing 2012, 9:8. 10.1186/1742-4933-9-8, 3402998, 22524430.
47. Pellegrini P, Contasta I, Del Beato T, Ciccone F, Berghella AM. Gender-specific cytokine pathways, targets, and biomarkers for the switch from health to adenoma and colorectal cancer. Clin Dev Immunol 2011, doi:10.1155/2011/819724.
48. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238. 10.1038/nature04753, 16648838.
49. Oukka M. Th17 cells in immunity and autoimmunity. Ann Rheum Dis 2008, 67:26-29. 10.1136/ard.2007.075101, 17720726.
50. Cua DJ, Kastelein RA. TGFß a 'double agent' in the immune pathology war. Nat Immunol 2000, 7:557-559.
51. Korn T, Anderson AC, Bettelli E, Oukka M. The dynamics of effector T cells and Foxp3+ regulatory T cells in the promotion and regulation of autoimmune encephalomyelitis. J Neuroimmunol 2007, 191:51-60. 10.1016/j.jneuroim.2007.09.009, 2289998, 17916388.
52. Greer JM, McCombe PA. Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J Neuroimmunol 2011, 234:7-18. 10.1016/j.jneuroim.2011.03.003, 21474189.
53. Korn T, Mitsdoerffer M, Croxford AL, Awasthi A, Dardalhon VA, Galileos G, Vollmar P, Stritesky GL, Kaplan MH, Waisman A, Kuchroo VK, Oukka M. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2008, 105:18460-18465. 10.1073/pnas.0809850105, 2587589, 19015529.
54. Nowak EC, Weaver CT, Turner H, Begum-Haque S, Becher B, Schreiner B, Coyle AJ, Kasper LH, Noelle RJ. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med 2009, 206:1653-1660. 10.1084/jem.20090246, 2722185, 19596803.
55. Contasta I, Totaro R, Pellegrini P, Del Beato T, Berghella AM. A gender-related action of IFNβ-therapy was found in multiple sclerosis. J Trasl Med 2012, 10:223. doi:10.1186/1479-5876-10-223.
56. Berghella AM, Contasta I, Del Beato T, Pellegrini P. The discovery of how gender influences age immunological mechanisms in health and disease, and the identification of ageing gender-specific biomarkers, could lead to specifically tailored treatment and ultimately improve therapeutic success rates. Immun Ageing 2012, 9:24. doi:10.1186/1742-4933-9-24, 10.1186/1742-4933-9-24, 3546894, 23148571.
57. Du L, Bayir H, Lai Y, Zhang X, Kochanek PM, Watkins SC, Graham SH, Clark RS. Innate gender-based proclivity in response to cytotoxicity and programmed cell death pathway. J Biol Chem 2004, 279:38563-38570. 10.1074/jbc.M405461200, 15234982.
58. Ortona E, Margutti P, Matarrese P, Franconi F, Malorni W. Redox state, cell death and autoimmune diseases: a gender perspective. Autoimmun Rev 2008, 7:579-584. 10.1016/j.autrev.2008.06.001, 18599384.
59. Cannizzo ES, Clement CC, Sahu R, Follo C, Santambrogio L. Oxidative stress, inflamm-aging and immunosenescence. J Proteomics. 2001, 74:2313-2323.
60. Buffenstein R, Edrey YH, Yang T, Mele J. The oxidative stress theory of aging: embattled or invincible? Insights from non-traditional model organisms. Age 2008, 30:99-109. 10.1007/s11357-008-9058-z, 2527631, 19424860.
61. Salminen A, Kaarniranta K, Kauppinen A. Inflammaging: disturbed interplay between autophagy and inflammasomes. Aging 2012, 4:166-175. 3348477, 22411934.
62. Hansen JM, Go YM, Jones DP. Nuclear and mitochondrial compartmentation of oxidative stress and redox signaling. Annu Rev Pharmacol Toxicol 2006, 46:215-234. 10.1146/annurev.pharmtox.46.120604.141122, 16402904.
63. Song JJ, Lee YJ. Differential role of glutaredoxin and thioredoxin in metabolic oxidative stress-induced activation of apoptosis signal regulating kinase 1. Biochem J 2003, 373:845-853. 10.1042/BJ20030275, 1223534, 12723971.
64. Gius D, Botero A, Shah S, Curry HA. Intracellular oxidation/reduction status in the regulation of transcription factors NF-B and AP-1. Toxicol Lett 1999, 106:93-106. 10.1016/S0378-4274(99)00024-7, 10403653.
65. Halliwell B, Gutteridge JM. Free radicals and antioxidant protection: mechanisms and significance in toxicology and disease. Human Toxicol 1988, 7:7-13.
66. Spitz DR, Sim JE, Ridnour LA, Galoforo SS, Lee YJ. Glucose deprivation-induced oxidative stress in human tumor cells: a fundamental defect in metabolism?. Ann NY Acad Sci 2000, 899:349-362.
67. Jones DP. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol 2008, 295:49-68.
68. Yoshida T, Nakamura H, Masutani H, Yodoi J. The involvement of thioredoxin and thioredoxin binding protein-2 on cellular proliferation and aging process. Ann N Y Acad Sci 2005, 1055:1-12.
69. Altschmied J, Haendeler J. Thioredoxin-1 and endothelial cell aging: role in cardiovascular diseases. Antioxid Redox Signal 2009, 11:1733-1740. 10.1089/ars.2008.2379, 19187002.
70. Mustacich D, Powis G. Thioredoxin reductase. Biochem J 2000, 346:1-8. 10.1042/0264-6021:3460001, 1220815, 10657232.
71. Becker K, Gromer S, Schirmer RH, Muller S. Thioredoxin reductase as a pathophysiological factor and drug target. Eur J Biochem 2000, 267:6118-6125. 10.1046/j.1432-1327.2000.01703.x, 11012663.
72. Powis G, Kirkpatrick DL, Angulo M, Baker A. Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chem Biol Interact 1998, 112:23-34.
73. Hirota K, Matsui M, Murata M, Takashima Y, Cheng FS, Itoh T, Fukuda K, Yodoi J. Nucleoredoxin, glutaredoxin, and thioredoxin differentially regulate NF-_B, AP-1, and CREB activation in HEK293 cells. Biochem Biophys Res Comm 2000, 274:177-182. 10.1006/bbrc.2000.3106, 10903915.
74. Hirota K, Nakamura H, Arai T, Ishii H, Bai J, Itoh T, Fukuda K, Yodoi J. Geranylgeranylacetone enhances expression of thioredoxin and suppresses ethanol-induced cytotoxicity in cultured hepatocytes. Biochem Biophys Res Comm 2000, 275:825-830. 10.1006/bbrc.2000.3392, 10973806.
75. Schwertassek U, Balmer Y, Gutscher M, Weingarten L, Preuss M, Engelhard J, Winkler M, Dick TP. Selective redox regulation of cytokine receptor signaling by extracellular thioredoxin 1. Embo J 2007, 26:3086-3097. 10.1038/sj.emboj.7601746, 1914094, 17557078.
76. Muta H, Boise LH, Fang L, Podack ER. CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. J Immunol 2000, 165:5105-5111.
77. McDonald PP, Cassatella MA, Bald A, Maggi E, Romagnani S, Gruss HJ, Pizzolo G. CD30 ligation induces Nuclear Factor kappa B activation in human T cell lines. Eur J Immunol 1995, 25:2870-2876. 10.1002/eji.1830251024, 7589085.
78. Contasta I, Totaro R, Berghella AM, Pellegrini P, Del Beato T, Carolei A, Adorno D. Soluble CD30: a biomarker for evaluating the clinical risk versus benefit of IFNβ1A treatment in multiple sclerosis patients. Int J Immunopathol Pharmacol 2010, 23:213-226.
79. Del Beato T, Berghella AM, Pellegrini P, Adorno D, Casciani CU. The role of the soluble CD30 serum level in colorectal cancer: a possible marker for a patient subset which could benefit from IL 2 biotherapy. Cancer Biother Radiopharm 1997, 12:297-304. 10.1089/cbr.1997.12.297, 10851480.
80. Pellegrini P, Berghella AM, Contasta I, Adorno D. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol 2003, 12:49-61. 10.1016/S0966-3274(03)00014-5, 14551032.
81. Pellegrini P, Totaro R, Contasta I, Berghella AM, Carolei A, Adorno D. CD30 antigen and Multiple Sclerosis: CD30 an important costimulator molecule and marker for a regulatory subpopulation of dendritic cells involved in maintaining the physiological balance between TH1/TH2 immune response and tolerance; the role of IFNβ1a in reestablishing this regulation in Multiple Sclerosis. Neuroimmunomodulation 2005, 12:220-234. 10.1159/000085654, 15990453.
82. Hargreaves PG, Al-Shamkhani AA. Soluble CD30 blocks transmembrane signaling by CD30. Eur J Immunol 2002, 32:163-173. 10.1002/1521-4141(200201)32:1<163::AID-IMMU163>3.0.CO;2-T, 11754357.
83. Pellegrini P, Contasta I, Berghella AM, Del Beato T, Adorno A. Classification of cancer stage using the immune system. Methods of Cancer Diagnosis, Therapy and Prognosis, Volume 7 Springer Publishing Company, Hayat MA, ISBN: 978-90-481-3185-3, 2010, chapter 14.
84. Berghella AM, Pellegrini P, Del Beato T, Ciccone F, Contasta I. The potential role of thioredoxin 1 and CD30 systems as multiple pathway targets and biomarkers in tumor therapy. Cancer Immunol Immunother 2011, 60:1373-1381. 10.1007/s00262-011-1068-5, 3176405, 21739118.
85. Janes KA, Yaffe MB. Data driven modelling of signal transduction networks. Nat Rev 2006, 7:820-828.
86. Bray D. Reasoning for results. Nature 2001, 412:863. 10.1038/35091132, 11528456.
87. Janes KA, Lauffenburger DA. A biological approach to computational models of proteomic networks. Curr Opin Chem Biol 2006, 10:73-80. 10.1016/j.cbpa.2005.12.016, 16406679.